Covered recipient · General Payments record
VEENA MALEPATI
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$1,584.33
- Reported across 80 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $386.37 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Pharmaceuticals, Inc | $116.37 | 1 |
| Novo Nordisk AS | $58.02 | 4 |
| Lilly USA, LLC | $55.53 | 2 |
| Abbott Laboratories | $40.00 | 2 |
| DEXCOM, INC. | $24.86 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $24.48 | 1 |
| Medtronic, Inc. | $19.75 | 1 |
| PFIZER INC. | $18.44 | 1 |
| GlaxoSmithKline, LLC. | $15.82 | 1 |
| Phathom Pharmaceuticals, Inc. | $13.10 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $19.51 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124868202 | CMS |
| Abbott Laboratories | $20.49 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124868204 | CMS |
| Dexcom, Inc. | $24.86 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153342503 | CMS |
| GlaxoSmithKline, LLC. | $15.82 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116542122 | CMS |
| Janssen Pharmaceuticals, Inc | $116.37 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077987630 | CMS |
| Lilly USA, LLC | $39.46 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135488378 | CMS |
| Lilly USA, LLC | $16.07 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135471421 | CMS |
| Medtronic, Inc. | $19.75 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117083919 | CMS |
| Novartis Pharmaceuticals Corporation | $24.48 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086771441 | CMS |
| Novo Nordisk Inc | $14.13 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097770557 | CMS |
| Novo Nordisk Inc | $13.74 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097101287 | CMS |
| Novo Nordisk Inc | $14.77 | 07/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097574828 | CMS |
| Novo Nordisk Inc | $15.38 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097236035 | CMS |
| PFIZER INC. | $18.44 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132121700 | CMS |
| Phathom Pharmaceuticals, Inc. | $13.10 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151049516 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.